2 November 2023
Latham & Watkins Advises Goldman Sachs Asset Management in US$150 Million Series B Funding for Rapport Therapeutics
Advising firms
Deal team
8 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Saad Khanani Lead | Latham & Watkins LLP | Partner | Not stated | Silicon Valley |
| Omar Ammash | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Autumn Schmidt | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Erica Kucharski | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Ben Haas | Latham & Watkins LLP | Partner | healthcare | Washington, D.C. |
| Jason Caron | Latham & Watkins LLP | Partner | healthcare | Washington, D.C. |
| Chad Jennings | Latham & Watkins LLP | Counsel | healthcare | Washington, D.C. |
| Judith Hasko | Latham & Watkins LLP | Partner | IP | Silicon Valley |
5 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 150m (US$150 million)
- What the figure measures
- Total transaction value
- Client
- Goldman Sachs Asset ManagementInvestor
- Counterparties
- Rapport Therapeutics, Inc. (Issuer)
Cormorant Asset Management (Investor)